Perspectives on adipose-derived stem/stromal cells as potential treatment for scarred vocal folds: Opportunity and challenges

Current Stem Cell Research and Therapy

Volumn 5, Issue 2, 2010, Pages 175-181

  Kumai, Yoshihiko ^a   Kobler, James B ^a   Herrera, Victoria L M ^b   Zeitels, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipose derived stem cell; Hepatocyte growth foactor; Regenerative therapy; Vocal fold scar

Indexed keywords

ANTIFIBROTIC AGENT; BIOMATERIAL; COLLAGEN TYPE 1; CYTOKINE; GROWTH FACTOR; DIFFERENTIATION ANTIGEN;

ADIPOSE DERIVED STEM CELL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL THERAPY; CELL VIABILITY; COLLAGEN SYNTHESIS; EMBRYONIC STEM CELL; FIBROBLAST; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; LARYNGITIS; METHODOLOGY; MYOFIBROBLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; REGENERATIVE MEDICINE; SCAR FORMATION; STEM CELL; STROMA CELL; TISSUE REGENERATION; VASCULARIZATION; VOCAL CORD; WOUND CONTRACTION; WOUND HEALING; ADIPOSE TISSUE; ANIMAL; CELL COMMUNICATION; CELL LINEAGE; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CICATRIX; HUMAN; INDUCED PLURIPOTENT STEM CELL; INJURIES; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; ANTIGENS, DIFFERENTIATION; CELL COMMUNICATION; CELL LINEAGE; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CICATRIX; FIBROBLASTS; GUIDED TISSUE REGENERATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LARYNGITIS; REGENERATIVE MEDICINE; VOCAL CORDS;

EID: 77954064962     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488810791268591     Document Type: Article

References (46)

1. Benninger MS, Alessi D, Archer S, et al. Vocal fold scarring: cur-rent concepts and management. Otolaryngol Head Neck Surg 1996;115: 474-82.
2. Thibeault L, Gray S, Bless M. Chan W, Ford C. Histologic andrheologic characterization of vocal fold scarring. J Voice 2002; 16:96-104.
3. Hirano S. Current treatment of vocal fold scarring. Curr Opin Oto-laryngol Head Neck Surg 2005; 13: 143-7.
4. Branski C, Verdolini K, Sandulache V, Rosen A, Hebda A. Vocalfold wound healing: a review for clinicians. J Voice 2006; 20(3):432-42.
5. Hansen JK, Thibeault SL. Current understanding and review of theliterature: Vocal fold scarring. J Voice 2006; 20(1): 110-20.
6. Kanemaru S, Nakamura T, Omori K, et al. Regeneration of thevocal fold using autologous mesenchymal stem cells. Ann OtolRhinol Laryngol 2003; 112: 915-20.
7. Kanemaru S, Nakamura T, Yamashita M, et al. Destiny of autolo-gous bone marrow-derived stromal cells implanted in the vocalfold. Ann Otol Rhinol Laryngol 2005; 114: 907-12.
8. Lee BJ, Wang SG, Lee JC, et al. The prevention of vocal foldscarring using autologous adipose tissue-derived stromal cells.Cells Tissues Organs 2006; 184: 198-204.
9. Hertegard S, Cedervall J, Svensson B, et al. Viscoelastic and his-tologic properties in scarred rabbit vocal folds after mesenchymalstem cell injection. Laryngoscope 2006; 116: 1248-54.
10. Cedervall J, Ahrlund-Richter L, Svensson B, et al. Injection ofembryonic stem cells into scarred rabbit vocal folds enhances heal-ing and improves viscoelasticity: short-term results. Laryngoscope 2007; 117: 2075-81.
11. Subotic R, Vecerina S, Krajina Z, Hirano M, Kurita S. Histologicalstructure of vocal fold lamina propria in foetal larynx. Acta Oto-laryngol 1984; 97: 403-6.
12. Zeitels SM, Healy GB. Laryngology and phonosurgery. N Engl JMed 2003; 349: 882-92.
13. Gray SD, Titze I, Alipour F, Hammond T. Biomechanical andhistologic observations of vocal fold fibrous proteins. Ann OtolRhinol Laryngol 2000; 109: 77-85.
14. Gray SD, Titze I, Chan R, Hammond T. Vocal fold proteoglycansand their influence on biomechanics. Laryngoscope 1999; 109:845-54.
15. Branski RC, Rosen CA, Verdolini K, Hebda PA. Acute vocal foldwound healing in a rabbit model. Ann Otol Rhinol Laryngol 2005;114: 19-24.
16. Hirano S, Minamiguchi S, Yamashita M, Ohno T, Kanemaru SI,Kitamura M. Histologic characterization of human scarred vocalfolds. J Voice 2009; 23(4): 399-407.
17. Hirano S, Bless D, Heisey D, Ford C. Roles of hepatocyte growthfactor and transforming growth factor beta1 in production of ex-tracellular matrix by canine vocal fold fibroblasts. Laryngoscope 2003; 113(1): 144-8.
18. Hirano S, Bless D, Rousseau B. Prevention of vocal fold scarringby topical injection of hepatocyte growth factor in a rabbit model.Laryngoscope 2004; 114: 548-56.
19. Kumai Y, Kobler J, Park H, et al. Crosstalk between adipose-derived stem/stromal cells and vocal fold fibroblasts in vitro. La-ryngoscope 2009; 119(4): 799-805
20. Rousseau B, Ge PJ, Ohno T, French LC, Thibeault SL. Extracellu-lar matrix gene expression after vocal fold injury in a rabbit modelAnn Otol Rhinol Laryngol 2008; 117: 598-603.
21. Conway K, Price P, Harding KG, Jiang WG. The molecular andclinical impact of hepatocyte growth factor, its receptor, activators,and inhibitors in wound healing. Wound Repair Regen 2006; 14: 2-10.
22. Schultz GS, Wysocki A. Interactions between extracellular matrixand growth factors in wound healing. Wound Repair Regen 2009;17: 153-62.
23. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-CanicM. Growth factors and cytokines in wound healing. Wound RepairRegen 2008; 16(5): 585-601.
24. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal stemcell-derived molecules reverse fulminant hepatic failure. PLoS One 2007; 2: e941.
25. Parekkadan B, van Poll D, Megeed Z, et al. Immunomodulation ofactivated hepatic stellate cells by mesenchymal stem cells. Bio-chem Biophys Res Commun 2007; 363: 247-52.
26. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells forregenerative medicine. Circ Res 2007; 100: 1249-60.
27. Schäffler A, Büchler C. Concise review: Adipose tissue-derivedstromal cells-basic and clinical implications for novel cell-basedtherapies. Stem Cells 2007; 25: 818-27.
28. Zhao DC, Lei JX, Chen R, et al. Bone marrow-derived mesenchy-mal stem cells protect against experimental liver fibrosis in rats.World J Gastroenterol 2005; 11: 3431-40.
29. Berry MF, Engler AJ, Woo YJ, et al. Mesenchymal stem cell injec-tion after myocardial infarction improves myocardial compliance.Am J Physiol Heart Circ Physiol 2006; 290: 2196-203.
30. Van Poll D, Parekkadan B, Borel Rinkes IHM, Tilles AW, Yar-mush ML. Mesenchymal stem cell therapy for protection and repairof injured vital organs. Cell Mol Bioeng 2008; 1(1); 42-50.
31. Shimode K, Iwasaki N, Majima T, et al. Bone marrow stromal cellsact as feeder cells for tendon fibroblasts through soluble factors.Tissue Eng 2007; 13(2): 333-41.
32. Kim WS, Park BS, Sung JH, et al. Wound healing effect of adi-pose-derived stem cells: a critical role of secretory factors on hu-man dermal fibroblasts. J Dermatol Sci 2007; 48: 15-24.
33. Hinz B. Formation and function of the myofibroblast during tissuerepair. J Invest Dermatol 2007; 127: 526-37.
34. Desmouliere A. Gabbiani G. Myofibroblast differentiation duringfibrosis. Exp Nephrol 1995; 3: 134-9.
35. Feng XH. Derynck R. Specificity and versatility in tgf-beta signal-ing through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-93.
36. Massague J, Seoane J, Wotton D. Smad transcription factors.Genes Dev 2005; 19: 2783-810.
37. Derynck R, Feng XH. TGF-beta receptor signaling. Biochim Bio-phys Acta 1997; 1333: F105-50.
38. Xia JL, Dai C, Michalopoulos GK, Liu Y. Hepatocyte growthfactor attenuates liver fibrosis induced by bile duct ligation. Am JPathol 2006; 168: 1500-12.
39. Kanangat S, Postlethwaite AE, Higgins GC, Hasty KA. Novelfunctions of intracellular IL-1ra in human dermal fibroblasts: im-plications in the pathogenesis of fibrosis. J Invest Dermatol 2006;126: 756-65.
40. Shephard P, Hinz B, Smola-Hess S, Meister JJ, Krieg T, Smola H.Dissecting the roles of endothelin, TGF-beta and GM-CSF on myo-fibroblast differentiation by keratinocytes. Thromb Haemost 2004;92: 262-74.
41. Wang M, Crisostomo PR, Herring C, Meldrum KK, Meldrum DR.Human progenitor cells from bone marrow or adipose tissue pro-duce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am J Physiol Regul Integr Comp Physiol2006: 291: 880-4.
42. Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renalinterstitial myofibroblast activation and intercepts Smad signaltransduction. Am J Pathol 2003; 163: 621-32.
43. Tokunou M, Niki T, Eguchi K, et al. c-MET expression in myofi-broblasts: role in autocrine activation and prognostic significance inlung adenocarcinoma. Am J Pathol 2001; 158: 1451-63.
44. Kilroy GE, Foster SJ, Wu X, et al. Cytokine profile of human adi-pose-derived stem cells: Expression of angiogenic, hematopoietic,and pro-inflammatory factors. J Cell Physiol 2007; 212: 702-9.
45. Wang SC, Ohata M, Schrum L, Rippe RA, Tsukamoto H. Expres-sion of interleukin-10 by in vitro and in vivo activated hepatic stel-late cells. J Biol Chem 1998; 273: 302-8.
46. Thompson KC, Trowern A, Fowell A, et al. Primary rat and mouse terleukin-10 during the course of activation In vitro. Hepatologyhepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation In vitro. Hepatology 1998; 28: 1518-24.